Recent News Releases

NEW YORK, NY, USA – May 13, 2021 – Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a...

New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...

Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...

KING OF PRUSSIA, PA, USA – MAY 6, 2021 – Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) for

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...

Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...

Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...